Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13259040 | 1.00 | FFAR1 (0.51) | FFAR1CA12CA1CA2TYR | |
| SCHEMBL13240131 | 0.86 | FFAR1 (0.54) | FFAR1CA12CA1CA2TYR | |
| SCHEMBL15096173 | 0.86 | FFAR1 (0.54) | FFAR1CA12CA1CA2TYR | |
| SCHEMBL1562411 | 0.86 | FFAR1 (0.54) | FFAR1CA12CA1CA2TYR | |
| SCHEMBL15091331 | 0.81 | ABCG2 (0.57) | CA12CA1CA2TYRCA7 | |
| SCHEMBL15091330 | 0.81 | ABCG2 (0.57) | CA12CA1CA2TYRCA7 | |
| SCHEMBL13967570 | 0.80 | CA12 (0.60) | CA12CA1CA2TYRCA7 | |
| SCHEMBL13285043 | 0.80 | CCNB2 (0.45) | FFAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7547543 | 0.80 | FFAR1 (0.48) | FFAR1HDAC3HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL7547540 | 0.80 | FFAR1 (0.48) | FFAR1HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2172472-B1 | Aminophosphonic acid derivative, salt thereof and modulator of S1P receptor | KYORIN SEIYAKU KK (JP) | 2012-12-26 | — | — | EP | disclosed |
| EP-1602660-B1 | AMINOPHOSPHONIC ACID DERIVATIVES, ADDITION SALTS THEREOF AND S1P RECEPTOR MODULATORS | KYORIN SEIYAKU KK (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-7759326-B2 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| EP-1431275-B1 | DIARYL ETHER DERIVATIVE, ADDITION SALT THEREOF, AND IMMUNOSUPPRESSANT | KYORIN SEIYAKU KK (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-2172472-A2 | Aminophosphonic acid derivative, salt thereof and modulator of S1P receptor | Kyorin Pharmaceutical Co., Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-7456157-B2 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-11-25 | — | — | US | disclosed |
| US-20080275008-A1 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KOHNO YASUSHI | 2008-11-06 | — | — | US | disclosed |
| US-20060160771-A1 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1602660-A1 | AMINOPHOSPHONIC ACID DERIVATIVES, ADDITION SALTS THEREOF AND S1P RECEPTOR MODULATORS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-6963012-B2 | Diaryl ether derivative, addition salt thereof, and immunosuppressant | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-11-08 | — | — | US | disclosed |
| US-20040242654-A1 | Diaryl ether derivative, addition salt thereof, and immunosuppressant | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1431275-A1 | DIARYL ETHER DERIVATIVE, ADDITION SALT THEREOF, AND IMMUNOSUPPRESSANT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160771-A1 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | S1PR1, S1PR2, S1PR5 | FFAR1 37/4885CA12 4597/4885CA1 4303/4885 |
| US-20080275008-A1 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | S1PR1, S1PR2, S1PR5 | FFAR1 37/4885CA12 4597/4885CA1 4303/4885 |
| US-20040242654-A1 | Diaryl ether derivative, addition salt thereof, and immunosuppressant | IL2, TSLP, HLA-DRB1 | FFAR1 3325/4885CA12 1188/4885CA1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.